Compare Biogen Inc (BIIB) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs WD 40 Company — how do they compare? Biogen Inc trades at $207.39 (market cap $30.13B), while WD 40 Company trades at $232.11 (market cap $3.13B). The key difference: Biogen Inc is far larger — about 9.6× WD 40 Company's market cap, and WD 40 Company pays a 1.75% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | WDFC | |
|---|---|---|
Market Cap | $30.13B | $3.13B |
Sector | Health | Technology |
52-Week High | $216.63 | $264.91 |
52-Week Low | $128.93 | $187.52 |
Enterprise Value | $37.20B | $3.18B |
Dividend Yield | — | 1.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
WD-40 Company (WDFC) trades at $232.9, down 0.69% today, with strong technical momentum showing bullish moving averages and key support at $230. The company reported impressive Q2 2026 earnings of $2.33 per share, beating estimates by 49%, while revenue growth continues with 2026 projections at $675 million. Recent news highlights institutional buying and positive analyst coverage, though valuation metrics remain elevated with a P/E of 35.39.
WDFC demonstrates solid fundamentals with consistent profitability (13.22% net margin) and strong brand positioning, but faces margin pressure from rising input costs. Analyst sentiment is mixed with 71% hold ratings, suggesting cautious optimism. Key risks include valuation concerns and cost inflation, while the company's dividend policy and global brand recognition provide stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
